Allergy
-
Multicenter Study Clinical Trial
The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma.
Mepolizumab and omalizumab are treatments for distinct but overlapping severe asthma phenotypes. ⋯ After directly switching from omalizumab to mepolizumab, patients with uncontrolled severe eosinophilic asthma experienced clinically significant improvements in asthma control, health status, and exacerbation rate, with no tolerability issues reported.